Cholangiocarcinoma (bile duct cancer) · line 2 · Futibatinib monotherapy (FOENIX-CCA2) — 2L+ FGFR2-fusion cholangiocarcinoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-FUTIBATINIB-CHOLANGIO-2L |
| ID | IND-CHOLANGIO-2L-FUTIBATINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-CHOLANGIOCARCINOMA |
| Sources | SRC-ESMO-BTC-2023 SRC-FOENIX-CCA2 SRC-NCCN-HEPATOBILIARY |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for FGFR2-fusion CCA. NCCN cat 2A (2025); FDA Sep 2022; EMA Jun 2023. SRC-FOENIX-CCA2 source live in KB (Goyal NEJM 2023). Pairs with IND-CHOLANGIO-2L-FGFR2-FUSION-PEMIGATINIB and (HISTORICAL) IND-CHOLANGIO-2L-INFIGRATINIB for FGFR2-fusion CCA 2L+ landscape. UA access: named-patient + Taiho EAP only.
Used By
Indication
IND-CHOLANGIO-2L-INFIGRATINIB- IND-CHOLANGIO-2L-INFIGRATINIB